- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05456100
Chinese American Cancer Survivors Writing Study
November 7, 2023 updated by: New York University
A Randomized Controlled Trial Testing Expressive Helping for Chinese American Cancer Survivors
The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Chinese Americans are one of the fastest growing immigrant groups in the United States, but there is still a lack of culturally-sensitive and linguistically-appropriate resources and interventions for this group.
To address this gap, the investigators will examine the efficacy and feasibility of Expressive Helping, a writing intervention designed to lead participants to write about their cancer experiences.
Participants will be adult cancer survivors of Chinese descent.
After screening and consent, eligible participants will be enrolled in a 1:1:1 randomized controlled trial.
Assessments of psychological symptoms will occur at baseline (prior to randomization), 1-month post-intervention, 3-months post-intervention, and 6-months post-intervention.
Study Type
Interventional
Enrollment (Estimated)
108
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: William Tsai, PhD
- Phone Number: (212)998-5552
- Email: will.tsai@nyu.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- Recruiting
- New York University
-
Contact:
- William Tsai
- Phone Number: 212-998-5552
- Email: will.tsai@nyu.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Over 18 years old.
- Prefer speaking in Mandarin Chinese or Cantonese, and able to read and write Simplified or Traditional Chinese.
- Within 5 years after completing primary treatment or have completed primary treatment but still on medication for managing cancer-related symptoms.
Exclusion Criteria:
- Difficulties with writing
- Current active participation in support groups (i.e., attending more than once per week)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Expressive Helping
Participants complete a 20-minute expressive writing session once per week for the first three weeks.
During Week 4, participants complete a 20-minute peer support writing session.
|
Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
|
Active Comparator: Expressive Writing
Participants complete a 20-minute expressive writing session once per week for four weeks.
|
Expressive writing involves emotional disclosure writing over four weeks.
|
Active Comparator: Factual Writing
Participants complete a 20-minute factual writing about their cancer diagnosis and treatment every week for four weeks.
|
Factual writing involves writing facts about cancer treatment and experiences over four weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment rates
Time Frame: through study completion, an average of 6 months
|
The number of participants screened for eligibility, percent eligible to participate, and percent of people who refuse to participate will be tracked.
|
through study completion, an average of 6 months
|
Retention rates
Time Frame: through study completion, an average of 6 months
|
Percent of participants who complete each stage of the study (e.g., baseline survey, writing sessions, follow-ups) will be tracked.
|
through study completion, an average of 6 months
|
Completion rate of writing sessions
Time Frame: through study completion, an average of 6 months
|
Assessed by dividing the number of writing sessions finished by the number of sessions assigned.
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in depressive symptoms assessed by the Center for Epidemiologic Studies Depression Scale
Time Frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Depressive symptoms will be measured with the 10-item Center for Epidemiologic Studies Depression Scale (CES-D).
The score can range from 0-30 and higher scores indicate more depressive symptoms.
|
Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Changes in anxiety symptoms assessed by the Generalized Anxiety Disorder Screener
Time Frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Anxiety symptoms will be measured with the 7-item GAD-7 scale (Spitzer et al., 2006).
This scale measures generalized anxiety symptoms in the past 7 days, has score ranges from 0-21 with higher scores indicating greater anxiety symptoms.
|
Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Changes in health-related quality of life assessed by the Functional Assessment of Cancer Therapy: General (FACT-G).
Time Frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Health-related quality of life will be measured by the 27-item FACT-G, which assess four domains: physical well-being, social well-being, emotional well-being and functional well-being.
The score ranges from 0-108 with higher scores indicating better quality of life.
|
Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Changes in perceived stress assessed by the Perceived Stress Scale.
Time Frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Perceived stress is measured by the 10-item Perceived Stress Scale (PSS).
The score ranges from 0-40 with higher scores indicating higher perceived stress.
|
Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Changes in cancer-related fatigue assessed by the Functional Assessment of Chronic Illness Therapy - Fatigue
Time Frame: Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Cancer-related fatigue is measured by the 13-item Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT).
The score ranges from 0-52 with higher scores indicating greater fatigue.
|
Baseline to 1-month follow-up, 3-month follow-up, and 6-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2022
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
July 6, 2022
First Submitted That Met QC Criteria
July 8, 2022
First Posted (Actual)
July 13, 2022
Study Record Updates
Last Update Posted (Estimated)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 20-0603
- 1K01MD014750 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
All IPD will be protected and maintained by the study team
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Expressive Helping
-
University of California, Los AngelesCompleted
-
New York UniversityCompletedNeoplasms | CancerUnited States
-
New York UniversityCompleted
-
Northwestern UniversityNational Cancer Institute (NCI); Hackensack Meridian Health; Lombardi Comprehensive...CompletedStem Cell Transplantation | Hematologic MalignancyUnited States
-
University of Texas at AustinUnknownPost Traumatic Stress DisorderUnited States
-
George Washington UniversityWorld Health Organization; Transcultural Psychosocial Organization Nepal; Socios... and other collaboratorsCompletedPsychological DistressNepal, Peru, Uganda
-
Baylor College of MedicineCompletedChildhood ObesityUnited States
-
Dartmouth-Hitchcock Medical CenterGlencliff HomeCompletedSerious Mental Illness | Psychosocial RehabilitationUnited States
-
University of TulsaCompletedTrauma | Post Traumatic Stress Disorder | Substance Abuse | Integrated Treatment | Incarcerated WomenUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedChild Externalizing BehaviorUnited States